Caplin Point Laboratories Q4 Results
- BSE: 524742
- NSE: CAPLIPOINT
- ISIN: INE475E01026
- Sector: Biotechnology & Drugs
BSE
1,701.50
-10.10 (-0.59%)
-10.10 (-0.59%)Volume5.57 K
Updated: Thu 19 Feb, 2026 | 15:29:47
NSE
1,702-9.50 (-0.56%)
-9.50 (-0.56%)Volume24.53 K
Updated: Thu 19 Feb, 2026 | 15:24:21
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Caplin Point Laboratories Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 351.43 | 372.36 | 1.31% | 324.39 | 8.34% |
| Depreciation/ Amortization | 17.04 | 19.28 | 5.19% | 16.40 | 3.90% |
| Operating Income | 151.02 | 170.41 | 3.37% | 128.83 | 17.22% |
| Net Income | 142.57 | 163.88 | 2.60% | 121.59 | 17.25% |
| Other Operating Expenses Total | 10.00 | 88.16 | -88.71% | 6.13 | 63.13% |
| Net Income Before Taxes | 176.67 | 203.89 | -0.33% | 146.03 | 20.98% |
| Total Revenue | 502.45 | 542.77 | 1.93% | 453.22 | 10.86% |
| Selling/ General/ Admin Expenses Total | 46.51 | 49.78 | -0.56% | 36.77 | 26.49% |
| Diluted Normalized EPS | 18.70 | 21.51 | 2.82% | 15.90 | 17.65% |